본문으로 건너뛰기
← 뒤로

Mitochondrial DNA copy number in leukocytes predicts long-term survival in prostate cancer.

2/5 보강
Clinical chemistry and laboratory medicine 📖 저널 OA 10.7% 2022: 0/2 OA 2023: 0/2 OA 2024: 0/1 OA 2025: 1/5 OA 2026: 2/17 OA 2022~2026 2026 Mitochondrial Function and Pathology
Retraction 확인
출처
PubMed DOI OpenAlex 마지막 보강 2026-04-29

PICO 자동 추출 (휴리스틱, conf 2/4)

유사 논문
P · Population 대상 환자/모집단
662 patients with prostate cancer.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
In a multivariate Cox regression model including age at diagnosis, androgen deprivation therapy, and risk group (based on PSA level, GS, and T stage), higher mtCN z-score remained a significant predictor of lower overall mortality (hazard ratio 0.85, 95 % confidence interval 0.74-0.98; p=0.029). [CONCLUSIONS] High leukocyte mtCN predicts better overall survival in patients with prostate cancer.
OpenAlex 토픽 · Mitochondrial Function and Pathology Prostate Cancer Diagnosis and Treatment Prostate Cancer Treatment and Research

Langsenlehner T, Paal K, Thurner EM, Langmüller M, Sternat R, Renner W

📝 환자 설명용 한 줄

[OBJECTIVES] Low mitochondrial DNA copy number (mtCN) in leukocytes is a predictor of all-cause mortality, independent of age and sex.

🔬 핵심 임상 통계 (초록에서 자동 추출 — 원문 검증 권장)
  • p-value p=0.009
  • p-value p=0.029
  • 추적기간 120 months

이 논문을 인용하기

↓ .bib ↓ .ris
APA Tanja Langsenlehner, Katarzyna Paal, et al. (2026). Mitochondrial DNA copy number in leukocytes predicts long-term survival in prostate cancer.. Clinical chemistry and laboratory medicine. https://doi.org/10.1515/cclm-2025-1464
MLA Tanja Langsenlehner, et al.. "Mitochondrial DNA copy number in leukocytes predicts long-term survival in prostate cancer.." Clinical chemistry and laboratory medicine, 2026.
PMID 41996660 ↗

Abstract

[OBJECTIVES] Low mitochondrial DNA copy number (mtCN) in leukocytes is a predictor of all-cause mortality, independent of age and sex. For malignant diseases, results about the prognostic value of leukocyte mtCN have been conflicting. Aim of the present study was to analyze the prognostic value of mtCN for long-term prostate cancer survival.

[METHODS] Blood samples of prostate cancer patients were obtained before initiation of radiotherapy. Relative mtCN was determined by a quantitative polymerase chain reaction method in 662 patients with prostate cancer. Main outcome was overall survival.

[RESULTS] During a follow-up time of 120 months, 218 (32.9 %) patients died. In a univariate Cox regression analysis, higher mtCN z-score was significantly associated with lower overall mortality (hazard ratio 0.83, 95 % confidence interval 0.72-0.96; p=0.009). In a multivariate Cox regression model including age at diagnosis, androgen deprivation therapy, and risk group (based on PSA level, GS, and T stage), higher mtCN z-score remained a significant predictor of lower overall mortality (hazard ratio 0.85, 95 % confidence interval 0.74-0.98; p=0.029).

[CONCLUSIONS] High leukocyte mtCN predicts better overall survival in patients with prostate cancer.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

같은 제1저자의 인용 많은 논문 (1)

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반